Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors [clinicaltrials:NCT00003125]
Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors [clinicaltrials:NCT00003125]
Bio2RDF identifier
NCT00003125
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00003125
identifiers.org URI
anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
RATIONALE: Vaccines may ...... nts who have advanced tumors.
brief title [clinicaltrials_vocabulary:brief-title]
Vaccine Therapy, Interleukin-2 ...... Patients With Advanced Tumors
collaborator [clinicaltrials_vocabulary:collaborator]
completion date [clinicaltrials_vocabulary:completion-date]
2004-11-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
OBJECTIVES: I. Evaluate ...... ll be accrued for this study.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
1999-11-01T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
is section 801 [clinicaltrials_vocabulary:is-section-801]
keyword [clinicaltrials_vocabulary:keyword]
stage II esophageal cancer
stage II pancreatic cancer
stage III esophageal cancer
stage III gastric cancer
stage III pancreatic cancer
stage IIIA breast cancer
stage IIIA non-small cell lung cancer
stage IIIB breast cancer
stage IIIB non-small cell lung cancer
stage IV breast cancer
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2011-03-22T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00003125
official title [clinicaltrials_vocabulary:official-title]
A Pilot Study of Sequential Va ...... nts With CEA Expressing Tumors
org study id [clinicaltrials_vocabulary:org-study-id]
CDR0000065885
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2004-11-01T00:00:00Z
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
U01CA062500
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
1998-01-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2007-05-01T00:00:00Z
identifier
clinicaltrials:NCT00003125
title
Vaccine Therapy, Interleukin-2 ...... Patients With Advanced Tumors
@en
type
label
Vaccine Therapy, Interleukin-2 ...... s [clinicaltrials:NCT00003125]
@en